Open access · US-GOV
via ClinicalTrials.gov Clinical trial
The TearAD Study: Tear Biomarkers for Alzheimer's Disease (AD) Screening and Diagnosis
Authors not listed
Maastricht University Medical Center · 2022
Abstract
The goal of this observational longitudinal study is to investigates whether tear fluid is a non-invasive source of biomarkers for Alzheimer's disease. The main aim of the study is to evaluate diagnostic accuracy measures (sensitivity and specificity) of tear and retinal biomarkers to discriminate individuals with and without neurodegeneration.
Tear fluid from participants will be collected non-invasively with Schirmer's strips, which is a small paper strip placed in the lower eye lid for a maximum of 5 minutes. Additionally, standard, ultra-wide field and cross-sectional retinal images will be obtained.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-10 MST
Cite this
APA
Anonymous. (2022). The TearAD Study: Tear Biomarkers for Alzheimer's Disease (AD) Screening and Diagnosis. <em>Maastricht University Medical Center</em>. https://clinicaltrials.gov/study/NCT05655793
Vancouver
Anonymous. The TearAD Study: Tear Biomarkers for Alzheimer's Disease (AD) Screening and Diagnosis. Maastricht University Medical Center. 2022.
BibTeX
@misc{anon2022TheTea,
title = {The TearAD Study: Tear Biomarkers for Alzheimer's Disease (AD) Screening and Diagnosis},
author = {Anonymous},
journal = {Maastricht University Medical Center},
year = {2022},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Eli Lilly and Company 2026
Open access · US-GOV
A Phase 1, Open Label, Multiple-Dose Study to Assess the Changes in Cerebrospinal Fluid Biomarkers for Alzheimer's Disease Following Treatment With LY3439539 in Participants With Symptomatic Alzheimer's Disease
AstraZeneca 2016
Open access · US-GOV
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Novo Nordisk A/S 2021
Open access · US-GOV
A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE)
Hillel Grossman 2018
Open access · US-GOV
Phase II Grape Seed Extract as Anti-Oligomerization Agent in Alzheimer's Disease
Amoneta Diagnostics SAS 2017
Open access · US-GOV
A Biomarker-chip Assay in Preserved Red Blood Cells for the Diagnosis of Alzheimer's Disease
National University Hospital, Singapore 2016
Open access · US-GOV